The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2021 | Liquid biopsy biomarkers for early detection and treatment prediction in HCC
Augusto Villanueva, MD, PhD, Icahn School of Medicine at Mount Sinai, New York, NY, outlines the need to develop more sensitive methods to detect biomarkers that are indicative of early tumor development in patients predisposed to hepatocellular carcinoma (HCC). Potential liquid biopsy options include the detection of circulating tumor DNA (ctDNA) and respective methylation, mutation, and extracellular vesical analysis, all with increased sensitivity to detect early tumor development for HCC. Detection of specific biomarkers is also clinically relevant in the prediction of tumor response to approved treatments and may aid clinicians in suggesting the best course of treatment for HCC patients with increased efficacy whilst mitigating hepatotoxicity. This interview was conducted at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
Disclosures
Augusto Villanueva, MD, PhD has received consulting fees from Boehringer Ingelheim, FirstWorld, Cambridge Healthcare Research and Genentech; advisory board fees from BMS, Gilead and NGM Pharmaceuticals; and research support from Eisai.
